{
  "id": 4872,
  "text": "Pharmacoepidemiol Drug Safꎬ 2014ꎬ 23: 456￣ 465.[53] Centers for Disease Control and Prevention (CDC).FDA li￣ censure of bivalent human papillomavirus vaccine ( HPV2ꎬ Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immuniza￣ tion Practices ( ACIP ) [ J ].",
  "ChatGPT_query": "Please create a <question> that closely aligns with the provided <text>. Ensure that the <question> is formulated in Chinese and does not explicitly reference the text. You may incorporate specific scenarios or contexts in the <question>, allowing the <text> to serve as a comprehensive and precise answer.\n\n<text>: Pharmacoepidemiol Drug Safꎬ 2014ꎬ 23: 456￣ 465.[53] Centers for Disease Control and Prevention (CDC).FDA li￣ censure of bivalent human papillomavirus vaccine ( HPV2ꎬ Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immuniza￣ tion Practices ( ACIP ) [ J ].\n\n<question>: \n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n",
  "ChatGPT_response_0": "目前，宫颈癌疫苗的接种建议主要来源于疾病控制与预防中心（CDC）和免疫实践顾问委员会（ACIP）的指导方针。针对宫颈癌的疫苗，如二价人乳头瘤病毒疫苗（HPV2，Cervarix），主要建议接种的对象是9至26岁的女性。这是为了在性行为开始之前提供保护，因为HPV疫苗在预防与性活动相关的HPV感染方面最为有效。\n\n接种程序通常包括几剂疫苗，需要在一段时间内完成，以确保最佳的免疫效果。早接种能够提供长期的保护，并可能减低未来患宫颈癌的风险。因此，公共卫生机构和医生往往建议在青春期或青春期初期就开始接种HPV疫苗。这不仅可以防止感染高风险的HPV类型，还可能降低由此引发的宫颈癌及其相关疾病的发生风险。对于具体接种时间和方案，建议遵从当地公共卫生部门和医疗专业人士的建议。",
  "query": "宫颈癌疫苗的现行接种建议是什么？",
  "ChatGPT_query_a": "You are HuatuoGPT-II, equipped with in-depth knowledge in medicine. Your task is to directly answer the user's <question> in Chinese. In formulating your response, you must thoughtfully reference the <reference text>, ensuring that your reply does not disclose your reliance on <reference text>. Aim to provide a comprehensive and informative response, incorporating relevant insights from <reference text> to best assist the user. Please be cautious to avoid including any content that might raise ethical concerns.\n\n<question>: 宫颈癌疫苗的现行接种建议是什么？\n\n<reference text>: Pharmacoepidemiol Drug Safꎬ 2014ꎬ 23: 456￣ 465.[53] Centers for Disease Control and Prevention (CDC).FDA li￣ censure of bivalent human papillomavirus vaccine ( HPV2ꎬ Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immuniza￣ tion Practices ( ACIP ) [ J ].\n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n\n<reply>: ",
  "response": "目前，宫颈癌疫苗的接种建议主要来源于疾病控制与预防中心（CDC）和免疫实践顾问委员会（ACIP）的指导方针。针对宫颈癌的疫苗，如二价人乳头瘤病毒疫苗（HPV2，Cervarix），主要建议接种的对象是9至26岁的女性。这是为了在性行为开始之前提供保护，因为HPV疫苗在预防与性活动相关的HPV感染方面最为有效。\n\n接种程序通常包括几剂疫苗，需要在一段时间内完成，以确保最佳的免疫效果。早接种能够提供长期的保护，并可能减低未来患宫颈癌的风险。因此，公共卫生机构和医生往往建议在青春期或青春期初期就开始接种HPV疫苗。这不仅可以防止感染高风险的HPV类型，还可能降低由此引发的宫颈癌及其相关疾病的发生风险。对于具体接种时间和方案，建议遵从当地公共卫生部门和医疗专业人士的建议。"
}